ANTIEMETIC TREATMENT WITH ORAL GRANISETRON IN PATIENTS RECEIVING MODERATELY EMETOGENIC CHEMOTHERAPY - A DOSE-RANGING STUDY

被引：39

作者：

BLEIBERG, HH ^{[1
]}

SPIELMANN, M ^{[1
]}

FALKSON, G ^{[1
]}

ROMAIN, D ^{[1
]}

机构：

[1] SMITHKLINE BEECHAM LABS PHARMACEUT,F-92731 NANTERRE,FRANCE

来源：

CLINICAL THERAPEUTICS | 1995年 / 17卷 / 01期

关键词：

D O I：

10.1016/0149-2918(95)80005-0

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The antiemetic efficacy and tolerability of four different oral doses of granisetron (0.25, 0.5, 1, and 2 mg twice daily [BID]) were compared in a randomized, double-blind, parallel-group, multicenter study involving 930 patients with malignant disease receiving moderately emetogenic chemotherapy over a 7- or 14-day period. On the first day of granisetron treatment, a statistically significant association between complete response and dose was seen (P = 0.001), with the maximum response (81.1%) achieved at a dose of 1 mg BID. The 24-hour complete response rate with granisetron 1 mg BID was significantly higher than with 0.25 mg BID (61.1%) or 0.5 mg BID (70.2%) (P < 0.009). The complete response rate for days 0 to 6 was significantly higher with granisetron at 1 mg BID (58.8%) than with 0.25 mg BID (43.7%) or 0.5 mg BID (53.6%) (P < 0.009). No advantage in terms of complete response rate was shown for 2 mg BID over 1 mg BID. Granisetron was well tolerated, and few patients required additional treatment with other antiemetics.

引用

页码：38 / 51

页数：14

共 27 条

[1]

Laszlo, Emesis as limiting toxicity in cancer chemotherapy, Anti-Emetics and Cancer Chemotherapy, pp. 1-5, (1983)

[2]

Gralla, An outline of anti-emetic treatment, Eur J Cancer Clin Oncol, 25, pp. S7-S11, (1989)

[3]

Kris, Gralla, Clark, Et al., Incidence, course and severity of delayed nausea and vomiting following the administration of high-dose cisplatin, J Clin Oncol, 3, pp. 1379-1384, (1985)

[4]

Lindley, Bernard, Fields, Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population, J Clin Oncol, 7, pp. 1142-1149, (1989)

[5]

Fetting, Grochow, Folstein, Et al., The course of nausea and vomiting after high-dose cyclophosphamide, Cancer Treat Rep, 66, pp. 1487-1493, (1982)

[6]

Sanger, New antiemetic drugs, Can J Physiol Pharmacol, 68, pp. 314-324, (1990)

[7]

Gralla, Itri, Pisko, Et al., Anti-emetic efficacy of high-dose metoclopramide: Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting, NEJM, 305, pp. 905-909, (1981)

[8]

Miner, Sanger, Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism, Br J Pharmacol, 88, pp. 497-499, (1986)

[9]

Soukop, McQuade, Hunter, Et al., Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer, Oncology, 49, pp. 295-304, (1992)

[10]

Marschner, Adler, Nagel, Et al., Double-blind randomized trial of the anti-emetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide, Eur J Cancer, 27, pp. 1137-1140, (1991)

← 1 2 3 →